Elacestrant
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Elacestrant: From ER+/HER2- Breast Cancer to Amenorrhea
One-Sentence Summary
Elacestrant is a selective estrogen receptor degrader (SERD) known clinically for treating ER+/HER2- breast cancer, though the evidence pack does not carry a formal original-indication record for this drug. The TxGNN model’s top prediction points to Amenorrhea, but this is supported by 0 clinical trials and 0 publications, and the model’s own mechanistic annotation flags the prediction as pharmacologically implausible.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in this evidence pack (known clinical use: ER+/HER2- breast cancer, SERD class) |
| Predicted New Indication | Amenorrhea |
| TxGNN Prediction Score | 92.50% |
| Evidence Level | L5 |
| EU Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (flagged as a High-severity data gap). Based on known information gathered from the evidence pack’s own rationale annotations, elacestrant is an estrogen receptor (ER) degrader used in ER+/HER2- breast cancer, where it antagonizes and degrades ER signaling to suppress tumor growth.
The model’s rank-1 prediction, however, links elacestrant to Amenorrhea — and the evidence pack’s own mechanistic assessment explicitly states this direction is biologically backwards: an ER-degrading drug is pharmacologically more likely to induce a menopausal-like hormonal state (including amenorrhea-related side effects) than to treat primary or secondary amenorrhea. The annotation describes this as “opposite to known pharmacology, mechanism not reasonable, purely a TxGNN embedding-similarity artifact.”
In other words, this top-ranked candidate should be read as a model-similarity signal rather than a biologically grounded hypothesis. None of the lower-ranked candidates in this pack fare better: rank 3 (multiple endocrine neoplasia) only pulled in breast-cancer trials unrelated to MEN (Grade C relevance), and rank 9 (hypogonadotropic hypogonadism) only pulled in COVID-19 anosmia literature that matched on the keyword “anosmia” rather than on the actual endocrine disease.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
Elacestrant is not currently authorized in this market (0 licenses on record; market status: Not Marketed). No authorization records are available to list.
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (Selective Estrogen Receptor Degrader, SERD) |
| Myelosuppression Risk | Please refer to the SmPC warnings and precautions |
| Emetogenicity Classification | Please refer to the SmPC warnings and precautions |
| Monitoring Items | Please refer to the SmPC warnings and precautions |
| Handling Protection | Please refer to the SmPC warnings and precautions |
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (Amenorrhea) has no clinical trial or literature support and is flagged by the evidence pack’s own mechanistic analysis as pharmacologically implausible (opposite direction to elacestrant’s known ER-degrading action). None of the other nine candidates in this pack are backed by disease-relevant evidence either — matched trials and literature are all off-target (breast cancer trials, COVID-19 anosmia papers). This is an L5, model-prediction-only case with no path to S1 safety screening.
To proceed, the following is needed:
- TFDA label warnings/contraindications (Blocking gap — required before any S1 safety pre-screening)
- Confirmed mechanism of action data from DrugBank
- A re-ranked or re-queried TxGNN output, since the current top candidates show weak or contradictory mechanistic links
- If pursuing further, disease-specific (not drug-name-only) clinical trial and literature searches for any retained candidate
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.